In October 2024, Nyrada announced the results of a preclinical coronary heart disease study,which showed that Xolatryp provided an 86% cardioprotective effect following myocardialischemic-reperfusion injury. Cut & paste ann. 21st.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.010(3.45%) |
Mkt cap ! $63.43M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 30.0¢ | 28.0¢ | $277.0K | 957.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 31270 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 130414 | 1 |
View Market Depth
| Last trade - 15.54pm 07/08/2025 (20 minute delay) ? |
| NYR (ASX) Chart |